Abstract
The development of effective cancer therapeutics is an important goal of modern biomedical sciences. To identify potential cancer therapeutic targets, the processes involved in tumorigenesis must be understood at all levels, which requires the development of model systems accurately mimicing tumor development. Cancer is the general name given to a variety of complex diseases characterised by uncontrolled cell proliferation. Cancer development is dependent not only on the changes occurring within the transformed cells, but also on the interactions of the cells with their microenvironment. The majority of our current understanding of carcinogenesis comes from the in vitro analysis of late-stage tumor tissue removed from cancer patients. While this has elucidated many genomic changes experienced by cancer cells, it provides little information about the factors influencing early-stage cancer development in vivo. Also certain hallmarks of cancer, such as metastasis and angiogenesis, are impossible to study in vitro. The mouse has become an important model for studying the in vivo aspects of human cancer development. Transgenic mouse models have been engineered to develop cancers, which accurately mimic their human counterparts, and have potential applications to test the effectiveness of novel cancer therapeutics. One of the most promising transgenic mouse models of human cancer arises from mice engineered with genomic instability. These transgenic models have been shown to develop human-like cancers and have the potential to provide insights into the molecular events occurring in earliest stages of tumorigenesis in vivo.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- Apc:
-
adenomatous polyposis coli
- ATM:
-
Ataxia-telangiectasia-mutated
- CIN:
-
chromosomal instabilities
- Cre/loxP:
-
recombinase systems (Cre recombinase with loxP recognition site)
- DDR:
-
DNA damage responses
- ES:
-
embryonic stem
- FAP:
-
Familial Adenomatous Polyposis
- Flp/FRT:
-
recombinase systems (Flp recombinase with FRT recognition site)
- HR:
-
homologous recombination
- Min:
-
multiple intestinal neoplasia
- MIN:
-
microsatellite instabilities
- NOD/SCID:
-
non-obese diabetic/severely compromized immunodeficient
- OIS:
-
oncogene-induced senescence
- Rb:
-
retinoblastoma gene (tumor suppressor gene)
- SCID:
-
severely compromized immunodeficient
- Terc:
-
telomerase RNA component also called hTR
- TERT:
-
telomerase reverse transcriptase subunit
- TSG:
-
tumor suppressor gene
- tTA:
-
transcriptional transactivator
- WT1:
-
Wilms’ tumor gene 1
- WT1-TCR:
-
WT1-specific T cell receptor
References
Atkin, N. B. (1986) Lack of reciprocal translocations in carcinomas. Cancer Genet Cytogenet, 21, 275–278.
Bartkova, J., Horejsi, Z., Koed, K., Kramer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., Orntoft, T., Lukas, J., and Bartkek, J. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumourigenesis. Nature, 434, 864–870.
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., Takaoka, M., Nakagawa, H., Tort, F., Fugger, K., Johanson, F., Sehested, M., Anderson, C. L., Dyrskjot, L., Arntoft, T., Lukas, J., Kittas, C., Helleday, T., Halazonetis, T. D., Bastek, J., and Gorgouli, V. G. (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature, 444, 633–637.
Blasco, M. A., Lee, H., Hande, M. P., Samper, E., Lansdorp, P. M., de Pinho, R. A., and Greide, C. W. (1997) Telomere shortening and tumour formation by mouse cells lacking telomerase RNA. Cell, 91, 25–34.
Blasco, M. A., Rizen, M., Greider, C. N., and Hanahan, D. (1996) Differential regulation of telomerase activity and telomerase RNA during multistage Tumourigenesis. Nat Genet, 12, 200–204.
Cahill, D. P., Kinzler, K. W., Vogelstein, K. B., and Lengauer, C. (1999) Genetic instability and Darwinian selection in tumours. Trends Cell Biol, 9, M57–M90.
Gonzalez-Suarez, E., Geserick, C., Flores, J. M., and Blasco, M. A. (2005) Antagonistic effects of telomerase on cancer and aging in K5-mTERT transgenic mice. Oncogene, 24, 2256–2270.
Gonzalez-Suarez, E., Samper, E., Flores, J. M., and Blasco, M. A. (2000) Telomerase-deficient mice with short telomeres are resistant to skin tumourigenesis. Nat Genet, 26, 114–117.
Gonzalez-Suarez, E., Samper, E., Ramirez, A., Flores, J. M., Martin-Caballero, J., Jorcano, J. L., and Blasco, M. A. (2001) Increased epidermal tumours and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mtert, in basal keratinocytes. EMBO J, 20, 2619–2630.
Gopinathan, A. and Tuveson, D. A. (2008) The use of GEM models for experimental cancer therapeutics. Dis Model Mech, 1, 83–86.
Gorgoulis, V. G., Vassiliou, L. F., Karakaidous, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., Ditullio, R. A., Kastrinakis, N. G., Levy, B., Kletsas, D., Yoneta, A., Hertyn, M., Kittas, C., and Halazonetis, T. D. (2005) Activation of the DNA damage checkpoint and genome instability in human precancerous lesions. Nature, 434, 907–913.
Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell, 86, 353–364.
Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell, 100, 57–70.
Hennighausen, L. (2000) Mouse models of breast cancer. Breast Cancer Res, 2, 2–7.
Heyer, J., Yang, K., Lipkin, M., Edelmann, W., and Kucherlapati, R. (1999) Mouse models of colorectal cancer. Oncogene, 18, 5325–5333.
Hudson, W. A., Li, Q., Le, C., and Kersey, J. H. (1998) Xenotransplantation of human lymphoid malignancies is optimised in mice with multiple immunological defects. Leukemia, 12, 2029–2033.
Ittner, L. M. and Gotz, J. (2007) Pronuclear injection for the production of transgenic mice. Nat Protoc, 2, 1206–1215.
Jonkers, J. and Berns, A. (2002) Conditional mouse models of sporadic cancer. Nature Rev Cancer, 2, 251–265.
Joyner, A. L. (1993) Gene Targeting: A Practical Approach, Oxford University Press, Oxford, UK.
Lengauer, C., Kinzler, K. W., and Vogelstein, B. (1998) Genetic instabilities in human cancers. Nature, 396, 643–649.
Loeb, L. A. (1991) Mutator Phenotype may be required for multistage carcinogenesis. Cancer Res, 51, 3075–3079.
Maser, R. S., Choudhury, B., Campbell, P. J., Feng, B., Wong, K., Protopopov, A., O’Neil, J., Gutierrez, A., Ivanova, E., Perna, I., Lin, E., Mani, V., Jiang, S., Weidemeyer, R., Kabbarah, O., Nogueira, C., Histen, G., Aster, J., Mansour, M., Duke, V., Foroni, L., Fielding, A. K., Goldstone, A. H., Rowe, J. M., Wang, Y. A., Look, A. T., Stratton, M. R., Chin, L., Futreal, P. A., and Depinho, R. A. (2007) Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature, 447, 966–971.
Micco, D. I., Fumagalli, R., Cicalese, M., Piccinin, A., Dasparini, S., Luise, P., Schurra, C., Garre, C., Nuciforo, M., Bensimon, P. G., Maestro, A. R., Pelicci, P. G., and Di Fagagna, F. A. (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature, 444, 638–642.
Moser, A. R., Pitot, H. C., and Dove, W. F. (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science, 247, 322–324.
Nishisho, I., Nakamura, Y., Miyoshi, Y., Miki, Y., Ando, H., Horii, A., Koyama, K., Utsunomiya, J., Baba, S., and Hedge, P. (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science, 253, 665–669.
O’Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277–285.
Prowse, K. R. and Greider, C. W. (1995) Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci USA, 92, 4818–4822.
Richmond, A. and Yingjun, S. (2008) Mouse xenograft models vs. GEM models for human cancer therapeutics. Dis Model Mech, 1, 78–82.
Sotillo, R., Hernando, E., Diaz-Rodriguez, E., Teruya-Feldstein, J., Cordon-Cardo, C., Lowe, S. W., and Benezra, R. (2007) Mad2 overexpression promotes aneuploidy and tumourigenesis in mice. Cancer Cell, 11, 9–23.
Su, L. K., Kinzler, K. W., Vogelstein, B., Preisinger, A. C., Moser, A. R., Luongo, C., Gould, K. A., and Dove, W. F. (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science, 265, 668–670.
Twombly, R. (2002) First clinical trials of endostatin yield lukewarm Results. J Natl Cancer Inst, 94, 1520–1521.
Wang, Y., Putnam, C. D., Kane, M. F., Zhang, W., Edelmann, L., Russell, R., Carrion, D. V., Chin, L., Kucherlapati, R., Kolodner, R. D., and Edelmann, W. (2005) Mutation in Rpa1 Results in defective DNA double-strand break repair, chromosomal instability and cancer in mice. Nat Genet, 37, 750–755.
Xue, S., Gao, L., Hart, D., Gillmore, R., Qusim, W., Thrasher, A., Apperley, J., Engels, B., Uckert, W., Morris, E., and Stauss, H. (2005) Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene–transduced human T cells. Blood, 106, 3062–3067.
Zhou, Z., Flesken-Nikitin, A., Corney, D. C., Wang, W., Goodrich, D. W., Roy-Burman, P., and Nikitin, A. Y. (2006) Synergy of p53 and Rb Deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res, 66, 7889–7898.
Acknowledgment
This work was supported by Health Research Board, Ireland, INTAS, and Science Foundation Ireland. S. C. is an NUIG Scholar.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Conmy, S., Nasheuer, HP. (2010). The Use of Transgenic Mice in Cancer and Genome Stability Research. In: Nasheuer, HP. (eds) Genome Stability and Human Diseases. Subcellular Biochemistry, vol 50. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-3471-7_17
Download citation
DOI: https://doi.org/10.1007/978-90-481-3471-7_17
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-3470-0
Online ISBN: 978-90-481-3471-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)